EN
SINOVAC Expands Strategic Partnership with Bio Farma, Bolstering Indonesia's Vaccine Supply
July 28, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced a strengthened alliance with Indonesian state-owned biopharmaceutical company PT Bio Farma, marking another milestone in the two companies' joint efforts to serve Indonesia's domestic vaccine market as well as international market.
The partnership agreement was signed on July 27, during the Indonesia-China Healthcare and Biotech Investment Forum held in Chengdu, the capital city of Sichuan Province in southwest China. It was witnessed by Indonesian government officials that included Budi Gunadi Sadikin, Indonesian Minister of Health; Djauhari Oratmangun, Indonesian Ambassador to China; and Arsjad Rasjid, Chairman of the Indonesian Chamber of Commerce and Industry.
Bio Farma, Indonesia's single and largest state-owned biopharmaceutical company, is an integral strategic partner for SINOVAC. The two companies partnered to successfully arm Indonesia with over 280 million doses of the inactivated COVID-19 vaccine, CoronaVac®, employing an efficient dual-pronged approach that enabled local filling of SINOVAC's finished product. CoronaVac® was the first COVID-19 vaccine available in Indonesia, a critical step in bringing the pandemic under control and protecting local populations.
SINOVAC remains committed to growth within the Indonesian market. Several of its products are available in addition to CoronaVac®, including the inactivated hepatitis A vaccine Healive® and the inactivated EV71 vaccine Inlive®. SINOVAC also has plans to introduce future products, including its varicella, influenza, and pneumococcal polysaccharide vaccines, to meet the region’s healthcare needs and further enhance local and national public health efforts.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Paneflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.
Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.
For more information, please see the Company’s website at www.sinovac.com.